Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-PD1 therapy induces lymphocyte-derived exosomal miRNA-4315 release inhibiting Bim-mediated apoptosis of tumor cells.

Cell death & disease - 11 Dec 2020

Guyon Nina, Garnier Delphine, Briand Joséphine, Nadaradjane Arulraj, Bougras-Cartron Gwenola, Raimbourg Judith, Campone Mario, Heymann Dominique, Vallette François M, Frenel Jean-Sébastien, Cartron Pierre-François

Abstract excerpt

Anti-PD1 immunotherapy, as a single agent or in combination with standard chemotherapies, has significantly improved the outcome of many patients with cancers. However, resistance to anti-PD1 antibodies often decreases the long-term therapeutic benefits. Despite this observation in clinical practice, the molecular mechanisms associated with resistance to anti-PD1 antibody therapy have not yet been elucidated. To...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Bcl-2-Like Protein 11

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Death

Share to Exosomes

Share to Mice, Nude

Share to Programmed Cell Death 1 Receptor

Share to Sulfonamides

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 33311449
DOI: 10.1038/s41419-020-03224-z
PMCID: PMC7733505

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-PD1 therapy induces lymphocyte-derived exosomal miRNA-4315 release inhibiting Bim-mediated apoptosis of tumor cells.PMID 33311449Read ↗

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomasSemantic proximity Read ↗

Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugsSemantic proximity Read ↗

Patritumab deruxtecan induces immunogenic cell deathSemantic proximity Read ↗

GPR183 mediates the capacity of the novel CD47-CD19 bispecific antibody TG-1801 to heighten ublituximab-umbralisib (U2) anti-lymphoma activitySemantic proximity Read ↗

BCL2 and miR-15/16: from gene discovery to treatmentSemantic proximity Read ↗

A Novel Model of Cancer Drug Resistance: Oncosomal Release of Cytotoxic and Antibody-Based DrugsSemantic proximity Read ↗

Strong activation of p53 by actinomycin D and nutlin-3a overcomes the resistance of cancer cells to the pro-apoptotic activity of the FAS ligandSemantic proximity Read ↗

Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.Semantic proximity Read ↗

BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase InhibitorsSemantic proximity Read ↗

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.Semantic proximity Read ↗

BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells.Semantic proximity Read ↗

Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.